Article

Dialysis Most Effective Treatment for Frail Patients with ESKD

Author(s):

Hemodialysis deemed the best form of dialysis in a new study focusing on elderly patients with end-stage kidney disease.

While effective for most, current dialysis guidelines might not be relevant for elderly or frail patients with end-stage kidney disease (ESKD).

A team, led by Chin Chin Ch'ng, Clinical Research Centre, Hospital Pulau Pinang, Ministry of Health Malaysia, determined the survival advantage for initiating dialysis in patents with ESKD that require renal replacement therapies.

The 3990-patient observational cohort on incident end-stage kidney disease patients from January 2007 to December 2008. In the study, patients contributed person-time from the date of the ESKD diagnosis until death, transplant, or the end of the study in December 2014.

The team performed an extended Cox regression model with time-varying exposure to dialysis to account for immortal time bias.

In the study, 70.2% patients initiated dialysis, 78.8% of which initiated hemodialysis (HD) with the remaining 21.2% initiated peritoneal dialysis (PD).

The investigators sought a primary outcome of all-cause mortality.

Starting dialysis resulted in a major improvement for patients, reducing the hazard of death in both elderly and non-elderly patients even after controlling for comorbidities (HR .58; 95% CI, .50-.68 and HR .76; 95% CI .69-.85, respectively).

“Dialysis improved survival in all incident ESKD patients,” the authors wrote. “The findings suggested a larger protection offered by HD. Although improve in survival from initiating dialysis was large, its true benefit should take overall quality of life into account.”

Many patients, particularly elderly patients, who require renal replacement therapies have delayed or rejected dialysis for a number of reasons.

In a 2019 patient survey, family members of patients with end-stage renal disease that are better informed about their end-of-life decisions rate report a higher quality of care.

In the 3369-patient survey, led by Claire A. Richards, PhD, University of Washington, investigators found that patients preparing for end-of-life decisions, improving access to concurrent receipt of dialysis and hospice services aids in improving the quality of end-of-life care for patients undergoing dialysis for end-stage renal disease.

Each patient that participated in the study was treated with maintenance dialysis at 111 US Department of Veterans Affairs medical centers and died between 2009-2015. The mean age of death for the study’s population was 70.6 years.

Overall, 937 patients (27.8%) stopped dialysis prior to death, while 2432 patients (72.2%) continued dialysis treatment until death.

“Patients who stopped dialysis were more likely to have been receiving hospice services at the time of death than patients who continued dialysis (544 patients [58.1%] vs 430 patients [17.7%]),” the authors said.

The investigators also found that patients who did not stop dialysis, receipt of hospice was linked to a higher probability of the patient’s family rating the quality of end-of-life care as excellent (60.5% vs. 40.0%).

In the US, there are about 500,000 patients currently receiving maintenance dialysis for treatment of end-stage renal disease, but approximately 25% of patients receiving maintenance dialysis for end-stage renal disease eventually halt treatment before death.

The study, “Survival advantage of initiating dialysis in elderly and non‐elderly incident end stage kidney disease patients,” was published online in Nephrology.

Related Videos
Christian Sadaka, MD: Significant Increase in Pediatric Gastroparesis Hospital Admissions After COVID-19
Developing Risk Assessment Tools for Viruses in School
Getting Black Men Involved in Their Health Care, Clinical Research
Patient Involvement in Advanced HF Treatment, with Ashley Malliett, DMSc, MPAS, PA-C
Aaron Henry, PA-C, MSHS: Regaining Black Male Patient Trust in the Doctor's Office
What Should the American Academy of Physician Associates Focus on in 2025?
Danielle O'Laughlin, PA-C, MS: Navigating Long-Term Risks, Family Planning in PCOS
© 2024 MJH Life Sciences

All rights reserved.